You are here
Plex Pharmaceuticals, Inc.
https://www.plexpharma.com/
UEI: U6KWJVLD1NU5
# of Employees: 7
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats
Amount: $600,000.00Project SummaryMosquito-borne members of the Flavivirus family including Zika virus (ZKV), Dengue virus (DNV) and West Nile virus (WNV), are classified as re-emerging pathogens due to the frequency an ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Advancing CAP4196 into in vivo Proof of Concept Translational Studies
Amount: $1,311,882.00Project SummaryCataract, the clouding of the eye lens is responsible for 51% of world blindness. According to World Health Organization nearly 18 million people are bilaterally blind from cataracts in ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts
Amount: $298,590.00Project SummaryCataract, the clouding of the eye lens is responsible for 51% of world blindness. According to World Health Organization nearly 18 million people are bilaterally blind from cataracts in ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Small molecule activators of alpha crystallin for non surgical treatment of cataracts
Amount: $299,173.00Project Summary Cataract the clouding of the eye lens is responsible for of world blindness According to World Health Organization nearly million people are bilaterally blind from cataract i ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease
Amount: $600,000.00DESCRIPTION provided by applicant Mosquito borne members of the Flavivirus family include four serotypes of dengue virus DENV and West Nile Virus WNV and are classified as re emerging pathog ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Discovery and Development of Novel Glucose Dependent Partial Glucokinase Activato
Amount: $201,930.00DESCRIPTION (provided by applicant): Type 2 diabetes (T2DM) is a chronic metabolic disease that affects the quality and longevity of life. Currently it is estimated that about 246 million people world ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Selective and dual-acting Hsp90 and TRAP1 inhibitors
Amount: $279,068.00DESCRIPTION (provided by applicant): Although the existing agents for treating cancer have shown promising results, the inherent genetic plasticity of the cancer cells continues to undermine the effic ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health
